#USA #Calgary #Innocan Pharma #LPT-CBD #SEC Amendment

Innocan Pharma Advances with U.S. Public Offering Plans

Innocan Pharma Corporation has recently announced significant developments in its pursuit of a public offering within the United States. The company, known for its focus on innovative pharmaceutical delivery platforms, has officially filed an amended registration statement with the U.S. Securities and Exchange Commission (SEC) concerning its proposed public offering of units, a move that underscores its growth ambitions.

Overview of the Registration Statement

Initially, Innocan filed its original registration statement on July 23, 2025. The amended version now submitted—categorized under Form F-1—includes essential details about the offering, such as the structure of the units. Each unit will consist of one common share and one share purchase warrant, granting investors the ability to purchase additional shares at a predetermined exercise price. This is intended to attract potential investors by providing them with not only common equity but also an opportunity for further investment.

Public Listing Aspirations

Innocan has applied for its common shares and warrants to be listed on the NYSE American under the ticker symbols